Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM6B | O15054 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | KDM5C | P41229 | 2/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.47 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14332932 | 0.86 | KDM4E (0.47) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL27619093 | 0.84 | MEN1 (0.38) | KDM4EMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL2810092 | 0.82 | LMNA (0.50) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL6999877 | 0.81 | TDP1 (0.50) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL437621 | 0.81 | NR4A2 (0.54) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL1732368 | 0.81 | SMYD3 (0.49) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL19764526 | 0.80 | ALOX15 (0.54) | KDM4EKDM4CMAPTKDM6BKDM5C | |
| SCHEMBL23535248 | 0.77 | CA12 (0.56) | KDM4EMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL6768352 | 0.75 | TDP1 (0.43) | KDM4EKDM4CMAPTKDM6BKDM4A | |
| SCHEMBL193423 | 0.75 | MAPT (0.59) | KDM4EKDM4CMAPTKDM6BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | UNIV JIMEI (CN) | 2025-09-04 | — | — | US | claimed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | claimed |
| CN-117883445-A | Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor | 集美大学 | 2024-04-16 | — | — | CN | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | UNIV JIMEI (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117883445-A | Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor | 集美大学 | 2024-04-16 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1883395-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127360-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | KDM4E 4670/4885KDM4C 4519/4885MAPT 4556/4885 |
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | XDH, DAO, KMO | KDM4E 1180/4885KDM4C 1872/4885MAPT 4081/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | KDM4E 3565/4885KDM4C 3490/4885MAPT 3782/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | KDM4E 2544/4885KDM4C 3493/4885MAPT 2171/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | KDM4E 4812/4885KDM4C 4826/4885MAPT 2227/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885KDM4C 3010/4885MAPT 2516/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | KDM4E 3021/4885KDM4C 4186/4885MAPT 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.